What is Collegium Pharmaceutical Inc Quarterly Revenue?

Collegium Pharmaceutical Inc Quarterly Revenue Collegium pharma Inc Jun-2026 Quarterly Revenue is $200 Million which is growth of 6.3% YoY.

What is Collegium Pharmaceutical Inc Quarterly Net Profit?

Collegium Pharmaceutical Inc Quarterly Net Profit Collegium pharma Inc Jun-2026 Quarterly Net Profit is $-15 Million which is growth of -225.6% YoY.

What is Collegium Pharmaceutical Inc Annual Revenue?

Collegium Pharmaceutical Inc Annual Revenue Collegium pharma Inc Dec-2025 Annual Revenue is $781 Million which is growth of 23.6% YoY.

What is Collegium Pharmaceutical Inc Annual Net Profit?

Collegium Pharmaceutical Inc Annual Net Profit Collegium pharma Inc Dec-2025 Annual Net Profit is $63 Million which is growth of -9.1% YoY.

What is Collegium Pharmaceutical Inc Total Shareholders Fund?

Collegium Pharmaceutical Inc Total Shareholders Fund Collegium pharma Inc Dec-2025 Total Shareholders Fund is $302 Million which is growth of 31.8% YoY.

What is Collegium Pharmaceutical Inc Total Assets?

Collegium Pharmaceutical Inc Total Assets Collegium pharma Inc Dec-2025 Total Assets is $1,657 Million which is growth of -0.4% YoY.

What is Collegium Pharmaceutical Inc Book Value Per Share?

Collegium Pharmaceutical Inc Book Value Per Share Collegium pharma Inc Book Value Per Share is $10 which is growth of 30.0% YoY.

What is Collegium Pharmaceutical Inc ROE?

Collegium Pharmaceutical Inc ROE Collegium pharma Inc ROE is 0% which is growth of 0% YoY.

What is Collegium Pharmaceutical Inc Cash From Operating Activity?

Collegium Pharmaceutical Inc Cash From Operating Activity Collegium pharma Inc Dec-2025 Cash From Operating Activity is $329 Million which is growth of 60.7% YoY.

What is Collegium Pharmaceutical Inc Net Cash Flow?

Collegium Pharmaceutical Inc Net Cash Flow Collegium pharma Inc Dec-2025 Net Cash Flow is $156 Million which is growth of 208.5% YoY.

Collegium Pharmaceutical Inc

XNAS: COLL

Falling Comet

Download real time

0.18(0.82%)

New 52W Low in past week

532.9K

XNAS Volume

XNAS 08 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Collegium pharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Collegium pharma Inc share price target, revenues, EPS, net income and more

Collegium pharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Collegium pharma Inc Jun-2026 Quarterly Revenue is $200 Million which is growth of 6.3% YoY.
NEGATIVE
Quarterly Net Profit Collegium pharma Inc Jun-2026 Quarterly Net Profit is $-15 Million which is growth of -225.6% YoY.

Collegium Pharmaceutical Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	199.9	193.5	205.5	209.4	188	177.8	182	159.3	145.3	144.9	149.7	136.7	135.6
CostOfRevenue_Q Cost Of Rev.	89.6	76.3	77.1	80.2	79.6	80.4	83.7	62.5	54.5	53.5	55.1	56.4	61.7
GrossProfit_Q Gross Profit	110.3	117.3	128.4	129.2	108.4	97.3	98.3	96.8	90.8	91.5	94.6	80.3	73.8
OEXPNS_Q Operating Exp. ⌄	106.6	86.4	67.6	67.1	73.6	76.4	63.1	62	43.3	42	32.9	35.3	38.2
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	106.6	86.4	67.6	67.1	73.6	76.4	63.1	62	43.3	42	32.9	35.3	38.2
ResearchAndDevlopmentExpenses_Q RnD Exp.	-	-	-	-	-	-	-	-	-	-
OP_Q Operating Profit	3.7	30.9	60.7	62.1	34.8	20.9	35.2	34.8	47.5	49.5	61.7	45	35.6
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	-17.2	-12.2	-15.7	-18.7	-18.1	-18.6	-20.8	-15.1	-11.2	-12.9	-15	-16.2	-17.8
Others_Q Other Interest Earned	2.3	3.7	3.6	3.1	2.4	2.2	1.8	3.3	4.4	4.5	4.3	4.5	4
IntExpNonOperating_Q Interest Exp. Non Operating	19.5	15.9	19.3	21.8	20.5	20.8	22.7	18.4	15.6	17.3	19.3	20.8	21.9
PBT_Q Profit Before Tax	-13.5	18.7	29	43.4	17	3.1	17.3	15.6	29.1	36.6	46.7	28.8	17.8
TAX_Q Tax	1.5	4.2	12.1	11.9	5	0.7	4.7	6.2	9.5	8.9	14.8	8.2	4.8
NICommonStockholders_Q Net Income Common Stockholders ⌄	-15.1	14.5	17	31.5	12	2.4	12.5	9.3	19.6	27.7	31.9	20.6	13
NP_Q Net Profit	-15.1	14.5	17	31.5	12	2.4	12.5	9.3	19.6	27.7	31.9	20.6	13
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-15.1	14.5	17	31.5	12	2.4	12.5	9.3	19.6	27.7	31.9	20.6	13
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-15.1	16	18.5	33.1	13.5	2.4	14	10.8	21.1	29.3	37.8	22.3	14.7
EPS_Q Basic EPS	-0.5	0.5	0.5	1	0.4	0.1	0.4	0.3	0.6	0.9	1	0.6	0.4
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-0.5	0.4	0.8	0.8	0.3	0.1	0.3	0.3	0.6	0.7	0.8	0.5	0.3
SHARE_Q Number Of Shares End	32.5	32.1	31.7	31.6	31.8	31.8	32.1	32.3	32.4	32.3	32.3	33.7	34.6
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-15.1	14.5	17	31.5	12	2.4	12.5	9.3	19.6	27.7	31.9	20.6	13
NormalizedIncome_Q Normalized Income	-15.1	14.5	29.6	31.5	11.7	1.8	10.4	11.8	24.5	27.7	31.9	20.6	13
InterestIncome_Q Interest Income	2.3	3.7	3.6	3.1	2.4	2.2	1.8	3.3	4.4	4.5	4.3	4.5	4
INT_Q Interest	19.5	15.9	19.3	21.8	20.5	20.8	22.7	18.4	15.6	17.3	19.3	20.8	21.9
NetInterestIncome_Q Net Interest Income	-17.2	-12.2	-15.7	-18.7	-18.1	-18.6	-20.8	-15.1	-11.2	-12.9	-15	-16.2	-17.8
EBIT_Q EBIT	6	34.6	48.3	65.2	37.5	23.9	39.9	34	44.7	54	66	49.6	39.7
EBITDA_Q EBITDA	70.8	90.5	104.7	121.7	94.1	80.5	96.4	75.7	80.2	89.4	101.5	86.7	78
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	89.6	76.3	77.1	80.2	79.6	80.4	83.7	62.5	54.5	53.5	55.1	56.4	61.7
ReconciledDepreciation_Q Reconciled Depr.	64.8	55.9	56.4	56.5	56.6	56.6	56.5	41.8	35.5	35.4	35.5	37.2	38.4
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-15.1	14.5	17	31.5	12	2.4	12.5	9.3	19.6	27.7	31.9	20.6	13
NormalizedEBITDA_Q Normalized EBITDA	70.8	90.5	120.7	121.7	93.7	79.7	93.5	79.9	87.3	89.4	101.5	86.7	78

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Collegium pharma Inc competitor comparison and performance snapshot within industry

Collegium pharma Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Collegium pharma Inc Dec-2025 Annual Revenue is $781 Million which is growth of 23.6% YoY.
NEGATIVE
Annual Net Profit Collegium pharma Inc Dec-2025 Annual Net Profit is $63 Million which is growth of -9.1% YoY.

Collegium Pharmaceutical Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
SR_A Total Rev. Ann. ⌄	18.9%	20.3%		780.6	631.5	566.8	463.9	276.9	310	296.7	280.4	28.5	1.7
TotalOperatingRevenues_A Operating Rev. Ann.	18.9%	20.3%	808.2	780.6	631.5	566.8	463.9	276.9	310	296.7	280.4	28.5	1.7
CostOfRevenue_A Cost Of Rev. Ann.	7.6%	19.5%	323.1	317.3	254.1	240.6	254.4	126.3	130.2	193.7	165.7	2.6	0.2	-
GrossProfit_A Gross Profit Ann.	30.3%	20.8%	485.1	463.3	377.3	326.2	209.5	150.6	179.8	103	114.7	25.9	1.5	-
OEXPNS_A Operating Exp. Ann.	17.4%	18.2%	327.7	284.8	210.4	159.2	176.2	128.4	123.6	126.8	135.4	101.3	95.6	26.9
OP_A Operating Profit Ann.	75%	26%	157.4	178.5	167	167	33.3	22.2	56.2	-23.8	-20.7	-75.5	-94.1	-26.9
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	-	-	-63.8	-71	-60	-67.7	-62.2	-21	-28.7	1	-18.4	0.6	-0.1	-0.4
Others_A Other Interest Earned Ann.	117.4%	124.1%	12.7	11.3	14	15.6	1.1	0	0.2	1.9	1.7	-	-	-
IntExpNonOperating_A Interest Exp. Non Operating Ann.	9.2%	23.3%	76.4	82.3	74	83.3	63.2	21	28.9	0.9	20.1	-	0.1	0.4
OtherExpenses_A Other Exp. Ann.	-	-		-14.8	-8.4	-23.5	-	-4.6	-	-	-	-	-	0.1
PBT_A PBT Ann.	-	27.4%	77.7	92.6	98.6	75.7	-28.9	-3.4	27.6	-22.7	-39.1	-74.9	-94.2	-27.3
TAX_A Tax Ann.	-	106.2%	29.8	29.8	29.4	27.6	-3.8	-74.9	0.8	-	-	-	-	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	18.6%	47.9	62.9	69.2	48.2	-25	71.5	26.8	-22.7	-39.1	-74.9	-94.2	-20
NP_A Net Profit Ann.	-	18.6%	47.9	62.9	69.2	48.2	-25	71.5	26.8	-22.7	-39.1	-74.9	-94.2	-27.3
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	18.6%	47.9	62.9	69.2	48.2	-25	71.5	26.8	-22.7	-39.1	-74.9	-94.2	-27.3
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	20.8%	52.5	68.9	75.1	54	-25	71.5	26.8	-22.7	-39.1	-74.9	-94.2	-20
EPS_A EPS Ann.	-	20.1%		2	2.1	1.4	-0.7	2.1	0.8	-0.7	-1.2	-2.5	-3.9	-1.5
DilutedEPS_A Diluted EPS Ann.	-	16.3%		1.7	1.9	1.3	-0.7	1.9	0.8	-0.7	-1.2	-2.5	-3.9	-1.5
SHARE_Q Number Of Shares End	-1.9%	-1.7%		31.7	32.1	32.3	33.6	34.1	34.6	33.7	33	32.5	27.1	20.7
TotalExpenses_A Total Exp. Ann.	11.8%	18.9%		602.1	464.5	399.8	430.6	254.7	253.8	320.5	301.1	103.9	95.8	26.9
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	18.6%	47.9	62.9	69.2	48.2	-25	71.5	26.8	-22.7	-39.1	-74.9	-94.2	-27.3
NormalizedIncome_A Normalized Income Ann.	-	22.2%	60.5	72.9	75.1	63.1	-25	74.9	26.8	-22.7	-39.1	-74.9	-94.2	-27.4
InterestIncome_A Interest Income Ann.	117.4%	124.1%	12.7	11.3	14	15.6	1.1	0	0.2	1.9	1.7	-	-	-
INT_A Interest Ann.	9.2%	23.3%	76.4	82.3	74	83.3	63.2	21	28.9	0.9	20.1	-	0.1	0.4
EBITDA_A EBITDA Ann.	32.3%	27.7%	387.7	401	341.7	308.3	173.3	86.6	118	-6.3	91.9	-74.9	-93.4	-26.6
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	7.6%	19.5%	323.1	317.3	254.1	240.6	254.4	126.3	130.2	193.7	165.7	2.6	0.2	-
ReconciledDepreciation_A Reconciled Depr. Ann.	17.6%	29.7%	233.6	226.1	169.2	149.3	138.9	68.9	61.6	15.5	110.9	0.6	0.7	0.2
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	18.6%	47.9	62.9	69.2	48.2	-25	71.5	26.8	-22.7	-39.1	-74.9	-94.2	-27.3
NormalizedEBITDA_A Normalized EBITDA Ann.	33.9%	28.6%	403.7	415.8	350.1	331.8	173.3	91.1	118	-6.3	91.9	-74.9	-93.4	-26.7

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

23.6%

2Y CAGR

17.4%

3Y CAGR

18.9%

5Y CAGR

20.3%

7Y CAGR

15.8%

Total Revenue Annual growth is higher than historical averages.

Net Profit Ann.

1Y CHG

-9.1%

2Y CAGR

14.2%

5Y CAGR

18.6%

Net Profit Annual is falling faster than historical averages.

Operating Exp. Ann.

1Y CHG

35.4%

2Y CAGR

33.8%

3Y CAGR

17.4%

5Y CAGR

18.2%

7Y CAGR

11.2%

10Y CAGR

26.6%

Operating Expenses Annual Cr growth is higher than historical averages.

Collegium pharma Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Collegium pharma Inc Dec-2025 Total Shareholders Fund is $302 Million which is growth of 31.8% YoY.
NEGATIVE
Total Assets Collegium pharma Inc Dec-2025 Total Assets is $1,657 Million which is growth of -0.4% YoY.

Collegium Pharmaceutical Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
TA_A Total Assets Ann. ⌄	12.2%	20.8%	1,656.8	1,663.6	1,143.3	1,174.1	692.1	643.8	306.3	291.2	135.6	162	97.7
CA_A Total Current Assets Ann.	18.1%	20%	691.4	482.3	537.6	420	315.5	277.9	255.7	237.5	133.5	158.6	96.9
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	30.6%	17.3%	386.7	162.8	310.6	173.7	186.4	174.1	170	146.6	118.7	153.2	95.7
Receivables_A Change In Account Receivables Ann.	4.9%	20.5%	211.3	228.5	179.5	183.1	105.8	83.3	73	78	10	2.1	-
Inventories_A Inventories Ann.	-4.2%	21.3%	40.9	35.6	32.3	46.5	17.4	15.6	9.6	7.8	1.8	1.3	-
OtherCurrentAssets_A Other Current Assets Ann.	217.5%	100%	3.2	2.7	0.1	0.1	0	0.1	0.1	1	0.5	0.3	0.2
TotalNonCurrentAssets_A Total Non Current Assets Ann.	8.6%	21.4%	965.4	1,181.3	605.7	754.1	376.5	366	50.6	53.7	2.1	3.4	0.8
NetPPE_A Net PPE Ann.	-15%	-10%	16.2	20.2	22	26.4	27.1	27.4	20.9	9.3	1.8	1	0.7
InvestmentsAndAdvances_A Investments & Advances Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	99.1%	51.1%	21.3	9.4	1.9	2.7	2.6	2.7	0.2	0.2	0.3	0.3	0.1
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	11.4%	24.2%	1,355.2	1,434.8	947.9	979.3	489.2	457.8	218.9	199.7	31.5	27.1	12.7
CL_A Total Current Liabilities Ann.	0.5%	12.9%	440	509.5	457.9	433.7	279.6	239.5	201.8	189.1	31.5	25.6	8.4
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	14.5%	16.8%	402.8	436.1	272.2	268.6	229.6	185.2	191.6	181.4	25.3	14.6	4.2
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	-42.9%	-8.8%	30.4	65.9	184.3	163.6	49.2	48.2	4.5	1.6	1.5	2.7	2.7
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	-	0.7	-	-	-	-	-	-	-		4.9	-
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-	-	2.4	3	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	18.8%	33.2%	915.1	925.2	490	545.6	209.6	218.4	17.1	10.5		1.5	4.2
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	12.9%	29.1%	784.5	793.4	490	545.6	209.6	218.4	17.1	9.9	-	1.5	4.2
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	15.7%	10.2%	301.7	228.8	195.4	194.8	202.9	186	87.4	91.6	104.1	134.9	85.1
EQCAP_A Equity Share Capital Ann.	15.7%	10.2%	301.7	228.8	195.4	194.8	202.9	186	87.4	91.6	104.1	134.9	85.1
CapitalStock_A Capital Stock Ann.	-	-	0	0	0	0	0	0	0	0	0	0	0
RetainedEarnings_A Retained Earnings Ann.	-	-	-101.1	-164	-233.2	-281.3	-256.3	-333.2	-359.9	-337.2	-298.1	-223.2	-129
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	-	0.3	0.1	0	-	-	-	-	-	-	-	-
TotalCapitalization_A Total Capitalization Ann.	13.8%	22.3%	1,082	1,016.8	679.3	733.3	404.6	395.6	95.1	101.4	104.1	136.4	89.2
TangibleAssets_A Tangible Assets Ann.	-	-	-513.8	-824.9	-360.1	-506.3	-65.8	-149.9	57.9	47.3	104.1	132.8	85.1
WC_A Working Capital Ann.	-	45.6%	251.4	-27.3	79.7	-13.7	36	38.4	54	48.4	102	133	88.5
InvestedCapital_A Invested Capital Ann.	7.4%	20.2%	1,111	1,081.3	862.6	895.8	452.9	443.1	98.9	103.1	105.6	139.1	91.9
TangibleBookValue_A Tangible Book Value Ann.	-	-	-513.8	-824.9	-360.1	-506.3	-65.8	-149.9	57.9	47.3	104.1	132.8	85.1
Borrowings_A Borrowings Ann.	4.7%	25%	814.9	859.3	674.3	709.2	258.8	266.6	21.6	11.5	1.5	4.2	6.8
NetDebt_A Net Debt Ann.	3.1%	47.4%	578.1	781.9	428.2	527.3	63.6	83	-	-	-	-	-
ShareIssued_A Share Issued Ann.	3.1%	3.3%	40.7	39.7	38.2	37.1	35.8	34.6	33.7	33.3	32.8	29.4	20.7
SHARE_Q Number Of Shares End	-1.9%	-1.7%	31.7	32.1	32.3	33.6	34.1	34.6	33.7	33	32.5	27.1	20.7

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

-0.4%

2Y CAGR

20.4%

3Y CAGR

12.2%

5Y CAGR

20.8%

7Y CAGR

28.2%

10Y CAGR

32.7%

Total Assets Annual is falling faster than historical averages.

Total Current Liabilities Ann.

1Y CHG

-13.6%

2Y CAGR

-2%

3Y CAGR

0.5%

5Y CAGR

12.9%

7Y CAGR

12.8%

10Y CAGR

48.6%

Total Current Liabilities Annual Cr is falling faster than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

31.9%

2Y CAGR

24.3%

3Y CAGR

15.7%

5Y CAGR

10.2%

7Y CAGR

18.6%

10Y CAGR

13.5%

Total ShareHolders Funds Annual growth is higher than historical averages.

Collegium pharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Collegium pharma Inc Book Value Per Share is $10 which is growth of 30.0% YoY.
NEUTRAL
ROE Collegium pharma Inc ROE is 0% which is growth of 0% YoY.

Collegium Pharmaceutical Inc, Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
ROA_A RoA Ann. %	-	-	-	4.93%	4.16%	-2.68%	10.71%	5.63%	-7.61%	-18.34%	-50.32%	-72.52%	-38.95%
ROE_A ROE Ann. %	-	-	-	32.62%	24.68%	-12.57%	36.77%	19.57%	-25.39%	-39.99%	-62.65%	-85.62%	-54.98%
ROIC_Q ROIC %	-	-	-	2.5	4.8	1.2	-4.5	3.2	-2.2	11.3	-17.1	-25.3	-9.8
OPMPCT_A OPM Ann. %	47.1%	4.7%	22.86%	26.44%	29.46%	7.18%	8.02%	18.14%	-8.00%	-7.38%	-264.95%	-5,498.66%	-
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	7.5	6.1	8	7.7	10.3	22.2	34.4	1.7	0.2	-
ASETTO_A Asset Turnover Ann. %	-	-	-	0.5	0.5	0.5	0.4	0.7	1	1.3	0.2	0	-
WCTO_A Working Capital Turnover Ann.	-	-17.5%	3.1	-23.2	7.1	-33.8	7.7	8.1	5.5	5.8	0.3	0
QuickRatio_A Quick Ratio Ann.	-	-	-	0.8	1.1	0.8	1.1	1.1	1.2	1.2	4.1	6.1	11.4
CRATIO_A Current Ratio Ann.	-	-	-	1	1.2	1	1.1	1.2	1.3	1.3	4.2	6.2	11.5
IC_A Interest Coverage Ratio Ann.	-	-	-	2.3	1.9	0.5	0.8	2	-24	-0.9	-	-1,000.9	-61.1
LTDE_A LT Debt To Equity Ann.	-	-	-	3.5	2.5	2.8	1	1.2	0.2	0.1	-	0	0.1

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Collegium pharma Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Cash From Operating Activity Collegium pharma Inc Dec-2025 Cash From Operating Activity is $329 Million which is growth of 60.7% YoY.
POSITIVE
Net Cash Flow Collegium pharma Inc Dec-2025 Net Cash Flow is $156 Million which is growth of 208.5% YoY.

Collegium Pharmaceutical Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
CFO_A Cash from Operating Act. Ann. ⌄	38.4%	28.5%	329.3	205	274.8	124.2	103.6	93.9	27.8	169.4	-67	-75.1	-21.6
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	18.6%	62.9	69.2	48.2	-25	71.5	26.8	-22.7	-39.1	-74.9	-94.2	-27.3
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	17.6%	29.7%	226.1	169.2	149.3	138.9	68.9	61.6	15.5	110.9	0.6	0.7	0.2
DepreciationAndAmortization_A Depreciation And Amortization Ann.	17.6%	29.7%	226.1	169.2	149.3	138.9	68.9	61.6	15.5	110.9	0.6	0.7	0.2
DeferredTax_A Deferred Tax Ann.	-	-	-25.7	-26.8	-2.2	-8.4	-78	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	-	-25.7	-26.8	-2.2	-8.4	-78	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	22.3%	13.9%	41.9	32.4	27.1	22.9	24.3	21.9	16.5	13.8	7.9	5.8	2.2
OtherNonCashItems_A Other Non Cash Items Ann.	-13.5%	-9.4%	5.5	6.7	8.4	8.5	3.4	9	0.3	19.3	-0	-0	-0
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	3.8	-55	21.7	-12.7	13.5	-25.3	18.2	64.6	-2.5	12.7	3.3
ChangeInReceivables_A Change In Receivables Ann.	-	-	17.2	-4.4	3.6	-21.8	-22.5	-10.4	5	-68.2	-7.8	-2.1	-
ChangeInInventory_A Change In Inventory Ann.	-	-	-5.4	13.9	14.2	48.3	-2.3	-8.3	-1.8	0.2	-0.5	-1.3	-
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	-	-	0.1	-50.4	2.5	-34.6	39.4	-5.1	12.9	132.1	11.8	12.1	1.7
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	-	-	-	-	-	-	-	-		-	2.3
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	-	-	-	-			-0.7	0.7	-	-	-
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-0.2	-	-		-	-	0.7	-	-4.9	4.9	-
CFI_A Cash from Investing Act. Ann. ⌄	-	-	-63.5	-287.8	-70.8	-573.7	-1.9	-373.8	-6.4	-24.4	-1	-3	-0.4
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-1.7	-1.7	-0.5	-1.6	-1.9	-5.6	-6.4	-5.5	-1	-0.5	-0.4
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-1.7	-1.7	-0.5	-1.6	-1.9	-5.6	-6.4	-5.5	-1	-0.5	-0.4
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-		-267.5		-572.1	-	-	-	-	-	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-		-267.5		-572.1	-	-	-	-	-	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-127	-111.2	-92.4	-	-	-	-	-	-	-	-
SaleOfInvestment_A Sale Of Investment Ann.	-	-	65.2	92.6	22	-	-	-	-	-	-	-	-
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
CFA_A Cash from Financing Act. Ann. ⌄	-	-	-110.2	-60.6	-140.2	436.7	-89.3	286.5	2	-117.2	33.5	135.6	116
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-	-70.4	7.5	-65.9	442.7	-50	281.4		10	-2.7	-2.7	-1.3
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-	-70.4	7.5	-65.9	442.7	-50	281.4		10	-2.7	-2.7	-1.3
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	-	-	-25.1	-60	-75	-14.1	-47.9		-	-0	34.3	137.3	72
CommonStockIssuance_A Common Stock Issuance Ann.	-	-	-	-	-	-	-		-	-	34.3	137.3	72
CommonStockPayments_A Common Stock Payments Ann.	-	-	-25.1	-60	-75	-14.1	-47.9	-	-	-0	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-20.4	-19.2	-8.4	-4	-4.2	-2.3	-0.8	-132.6	-0.1	-	-0
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	12.7%	7.4%	252.2	96.6	240	176.2	189	176.7	170	146.6	118.7	153.2	95.7
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	88.1%	155.6	-143.4	63.8	-12.7	12.3	6.6	23.4	27.8	-34.5	57.5	94.1
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-20%	-10.7%	96.6	240	176.2	189	176.7	170	146.6	118.8	153.2	95.7	1.6
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	79.4%	160.5%	60	52.1	24.2	10.4	3	0.5	-	-	-	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	9.4%	29.4%	68.8	62.4	73.3	52.5	17.6	19	0.7	0.6	0.1	0.3	0.4
CapitalExpenditure_A Capex Ann.	-	-	-1.7	-1.7	-0.5	-1.6	-1.9	-373.8	-6.4	-24.4	-1	-3	-0.4
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	-	-	-	-	-	-	-		-	-	34.3	137.3	116.8
IssuanceOfDebt_A Issuance Of Debt Ann.	3%	11.3%	565.2	313.2	235.2	517.7		330.4		10	-	-	-
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-635.6	-305.7	-301.1	-75	-50	-49			-2.7	-2.7	-1.3
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-25.1	-60	-75	-14.1	-47.9	-	-	-0	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	38.8%	-	327.6	203.3	274.3	122.6	101.6	-279.8	21.3	145	-68	-78	-21.9

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

60.6%

2Y CAGR

9.5%

3Y CAGR

38.4%

5Y CAGR

28.5%

7Y CAGR

10%

Cash from Operating Activity Annual growth is higher than historical averages.

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

New 52W Low in past week

Collegium pharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Collegium pharma Inc - Forecaster

Forecaster Analyst Estimates for Collegium pharma Inc share price target, revenues, EPS, net income and more

Collegium pharma Inc - Earnings Report - Quarterly Results

Collegium pharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Collegium pharma Inc Jun-2026 Quarterly Revenue is $200 Million which is growth of 6.3% YoY.

Quarterly Net Profit Collegium pharma Inc Jun-2026 Quarterly Net Profit is $-15 Million which is growth of -225.6% YoY.

Collegium pharma Inc - Competitors/Peers

Collegium pharma Inc competitor comparison and performance snapshot within industry

Collegium pharma Inc - Earnings Report - Annual Results

Collegium pharma Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue Collegium pharma Inc Dec-2025 Annual Revenue is $781 Million which is growth of 23.6% YoY.

Annual Net Profit Collegium pharma Inc Dec-2025 Annual Net Profit is $63 Million which is growth of -9.1% YoY.

Collegium pharma Inc - Balance Sheet

Collegium pharma Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Collegium pharma Inc Dec-2025 Total Shareholders Fund is $302 Million which is growth of 31.8% YoY.

Total Assets Collegium pharma Inc Dec-2025 Total Assets is $1,657 Million which is growth of -0.4% YoY.

Collegium pharma Inc - Ratios

Collegium pharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share Collegium pharma Inc Book Value Per Share is $10 which is growth of 30.0% YoY.

ROE Collegium pharma Inc ROE is 0% which is growth of 0% YoY.

Collegium pharma Inc - Cash Flow

Collegium pharma Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity Collegium pharma Inc Dec-2025 Cash From Operating Activity is $329 Million which is growth of 60.7% YoY.

Net Cash Flow Collegium pharma Inc Dec-2025 Net Cash Flow is $156 Million which is growth of 208.5% YoY.